The introduction of Retatrutide ZPHC, at a strength of 120mg, is generating considerable interest within the healthcare community. This innovative dual GIP and GLP-1 agonist medication seems to provide impressive improvements in fat loss compared to previous therapies. Preliminary research trials have shown marked decreases in body fat percentage,